Compounds > sulfachlorpyrazine
Page last updated: 2024-12-08

sulfachlorpyrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sulfachlorpyrazine : A sulfonamide containing a 5-chloropyrazin-2-yl moiety linked to the amide nitrogen; principally used in veterinary medicine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID164867
CHEBI ID145370
SCHEMBL ID6752479
MeSH IDM0144511

Synonyms (19)

Synonym
AC-7628
sulfachlorpyrazine
1672-91-9
CHEBI:145370
4-amino-n-(5-chloropyrazin-2-yl)benzenesulfonamide
4-amino-n-(5-chloropyrazin-2-yl)benzene-1-sulfonamide
sulphachloropyrazine
96r84uz2xa ,
unii-96r84uz2xa
4-amino-n-(5-chloropyrazinyl)benzenesulfonamide
benzenesulfonamide, 4-amino-n-(5-chloropyrazinyl)-
benzenesulfonamide, 4-amino-n-(5-chloro-2-pyrazinyl)-
4-amino-n-(5-chloropyrazinyl)-benzenesulfonamide
SCHEMBL6752479
AKOS025402285
F1905-8633
DTXSID50937296
4-amino-n-(5-chloropyrazin-2(1h)-ylidene)benzene-1-sulfonamide
Q27271921

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Therefore, the suggested withdrawal period for SPZ-DVD suspension should be 7 days after dosing for seven successive days."( Determination of sulphachloropyrazine-diaveridine residues by high performance liquid chromatography in broiler edible tissues.
Bu, S; Li, Y, 2016)		0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's1 (8.33)18.2507
2000's2 (16.67)29.6817
2010's7 (58.33)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.59 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
sulfamonomethoxine
Sulfamonomethoxine: Long acting sulfonamide antibacterial agent.		2.110benzenes;
sulfonamide
nicarbazin
Nicarbazin: An equimolar complex of 4,4'-Dinitrocarbanilide and 2-Hydroxy-4,6-dimethylpyrimidine. A coccidiostat for poultry.		2.610organic molecular entity
clopidol
pharmcoccide: Russian drug; no other info available 1/1/79		2.610chloropyridine
diaveridine
diaveridine: RN given refers to parent cpd; structure. diaveridine : An aminopyrimidine in which the pyrimidine ring carries amino substituents at C-2 and C-4 and a 3,4-dimethoxybenzyl group at C-5. A folic acid antagonist, it is used as a synergist with sulfonamides against the parasitic Eimeria species.		2.1310aminopyrimidineantiparasitic agent;
drug allergen
toltrazuril
toltrazuril: structure in first source		1.9810aromatic ether
sulfur
Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.		2.1310chalcogen;
nonmetal atom		macronutrient
oxytetracycline, anhydrous
Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.		2.0110
ConditionIndicatedRelationship StrengthStudiesTrials
Besnoitiasis
[description not available]		02.9340
Poultry Diseases
Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.		02.9340
Weight Gain
Increase in BODY WEIGHT over existing weight.		02.610
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0710
Infection, Toxoplasma gondii
[description not available]		02.0710
Toxoplasmosis
The acquired form of infection by Toxoplasma gondii in animals and man.		02.0710
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0510
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9810
Cecal Diseases
Pathological developments in the CECUM.		01.9810